Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Capdevila, Jaume; Fazio, Nicola; Lopez, Carlos; Teulé, Alexandre; Valle, Juan W; Tafuto, Salvatore; Custodio, Ana; Reed, Nicholas; Raderer, Markus; Grande, Enrique; Garcia-Carbonero, Rocio; Jimenez-Fonseca, Paula; Hernando, Jorge; Bongiovanni, Alberto; Spada, Francesca; Alonso, Vicente; Antonuzzo, Lorenzo; Spallanzani, Andrea; Berruti, Alfredo; La Casta, Adelaida; Sevilla, Isabel; Kump, Patrizia; Giuffrida, Dario; Merino, Xavier; Trejo, Lorena; Gajate, Pablo; Matos, Ignacio; Lamarca, Angela; Ibrahim, Toni

doi:10.1200/JCO.20.03368

Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression to targeted agents (TAs). We investigated the efficacy and safety of lenvatinib in patients with previously treated advanced GEP-NETs.

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) / Capdevila, Jaume; Fazio, Nicola; Lopez, Carlos; Teulé, Alexandre; Valle, Juan W; Tafuto, Salvatore; Custodio, Ana; Reed, Nicholas; Raderer, Markus; Grande, Enrique; Garcia-Carbonero, Rocio; Jimenez-Fonseca, Paula; Hernando, Jorge; Bongiovanni, Alberto; Spada, Francesca; Alonso, Vicente; Antonuzzo, Lorenzo; Spallanzani, Andrea; Berruti, Alfredo; La Casta, Adelaida; Sevilla, Isabel; Kump, Patrizia; Giuffrida, Dario; Merino, Xavier; Trejo, Lorena; Gajate, Pablo; Matos, Ignacio; Lamarca, Angela; Ibrahim, Toni. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1527-7755. - STAMPA. - 39:(2021), pp. 2304-2312. [10.1200/JCO.20.03368]